Abattis Bioceuticals Corp. (ATTBF)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT
Abattis Bioceuticals Income Statement
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | 2010 - 2014 |
|---|---|---|---|---|---|---|
Period Ending | Sep '19 Sep 30, 2019 | Sep '18 Sep 30, 2018 | Sep '17 Sep 30, 2017 | Sep '16 Sep 30, 2016 | Sep '15 Sep 30, 2015 | 2010 - 2014 |
| Revenue | 0.36 | 0.01 | - | - | 0.09 | Upgrade
|
| Revenue Growth (YoY) | 4163.24% | - | - | - | 1090.93% | Upgrade
|
| Cost of Revenue | 0.12 | 0 | - | - | 0.03 | Upgrade
|
| Gross Profit | 0.24 | 0.01 | - | - | 0.06 | Upgrade
|
| Selling, General & Admin | 4.06 | 15.21 | 4.6 | 2.02 | 2.55 | Upgrade
|
| Research & Development | - | 0.03 | 0.01 | 0.04 | 0.08 | Upgrade
|
| Operating Expenses | 4.15 | 15.78 | 5.43 | 2.26 | 3.06 | Upgrade
|
| Operating Income | -3.91 | -15.78 | -5.43 | -2.26 | -3 | Upgrade
|
| Interest Expense | -0.04 | -4.33 | - | -0.01 | -0.02 | Upgrade
|
| Earnings From Equity Investments | - | -0.87 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.25 | -0.02 | -0 | -0.01 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.31 | -28.31 | 0.07 | -0.07 | -0.24 | Upgrade
|
| EBT Excluding Unusual Items | -3.39 | -49.31 | -5.36 | -2.35 | -3.25 | Upgrade
|
| Merger & Restructuring Charges | - | -11.35 | - | - | - | Upgrade
|
| Impairment of Goodwill | - | -10.43 | - | - | -0.51 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.33 | -10.92 | - | -0.01 | -0.3 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 5.07 | - | - | -0.39 | Upgrade
|
| Asset Writedown | -0.05 | -0.04 | -0.95 | - | -1.83 | Upgrade
|
| Other Unusual Items | 0.06 | -0.68 | -0.74 | -0.05 | 0.29 | Upgrade
|
| Pretax Income | -3.06 | -77.65 | -7.05 | -2.41 | -5.99 | Upgrade
|
| Income Tax Expense | - | - | - | - | -0.42 | Upgrade
|
| Earnings From Continuing Operations | -3.06 | -77.65 | -7.05 | -2.41 | -5.57 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -0.88 | - | - | Upgrade
|
| Net Income to Company | -3.06 | -77.65 | -7.93 | -2.41 | -5.57 | Upgrade
|
| Minority Interest in Earnings | 0.02 | -0.36 | 0.29 | 0.07 | 1.1 | Upgrade
|
| Net Income | -3.04 | -78.01 | -7.63 | -2.34 | -4.47 | Upgrade
|
| Net Income to Common | -3.04 | -78.01 | -7.63 | -2.34 | -4.47 | Upgrade
|
| Shares Outstanding (Basic) | 470 | 323 | 149 | 95 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 470 | 323 | 149 | 95 | 69 | Upgrade
|
| Shares Change (YoY) | 45.83% | 117.02% | 56.50% | 38.04% | 41.01% | Upgrade
|
| EPS (Basic) | -0.01 | -0.24 | -0.05 | -0.02 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.24 | -0.05 | -0.02 | -0.06 | Upgrade
|
| Free Cash Flow | 9.35 | -8.51 | -1.65 | -0.78 | -1.86 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | -0.03 | -0.01 | -0.01 | -0.03 | Upgrade
|
| Gross Margin | 67.63% | 77.37% | - | - | 68.11% | Upgrade
|
| Operating Margin | -1095.65% | -188474.47% | - | - | -3262.40% | Upgrade
|
| Profit Margin | -852.40% | -931940.11% | - | - | -4864.64% | Upgrade
|
| Free Cash Flow Margin | 2620.32% | -101698.69% | - | - | -2021.59% | Upgrade
|
| EBITDA | -3.84 | -15.74 | -5.34 | -2.13 | -2.82 | Upgrade
|
| D&A For EBITDA | 0.07 | 0.04 | 0.09 | 0.13 | 0.18 | Upgrade
|
| EBIT | -3.91 | -15.78 | -5.43 | -2.26 | -3 | Upgrade
|
| Advertising Expenses | 1.17 | 3.14 | 0.14 | 0.08 | 0.13 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.